Peripartum cardiomyopathy: An ominous complication of pregnancy

American Journal of Critical Care

Volumn 9, Issue 5, 2000, Pages 362-366

  Futterman, Laurie G ^a   Lemberg, Louis ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CARDIOMYOPATHY; CASE REPORT; FEMALE; HUMAN; MULTIPLE PREGNANCY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; TWINS;

ADULT; CARDIOMYOPATHIES; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY, MULTIPLE; TWINS;

EID: 0034269173     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2000.9.5.362     Document Type: Article

References (11)

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;XLIV:964-968.
2. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
3. Lemberg L. Digitalis in congestive heart failure: fact or fancy. Arch Intern Med. 1978;138:451-452.
4. Packer M. Positive inotropic agents for chronic heart failure: a new perspective. Heart Failure. 1993;136-147.
5. Lemberg L. Changing concepts in the management of congestive heart failure. J Fla Med Assoc. 1978;65:415-420.
6. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of irnmunosuppressive therapy for myocarditis. N Engl JMed. 1995;333:269-275.
7. Heider AL, Kuller JA, Strauss RA, Wells SR. Peripartum cardiomyopathy: a review of the literature. Obstet Gynecol Surv. 1999;54:526-531.
8. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999;34:177-180.
9. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997;176:182-188.
10. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J. 1995; 130:860-870.
11. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (NIH) Workshop recommendations and review. JAMA. 2000;283:1183-1188.